Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hypha Labs, Inc. (FUNI)
USD0.02
+0.00 (+5.68%)
US OTC Healthcare Medical - Diagnostics & Research
Address
5940 S. Rainbow Boulevard 89118
Las Vegas, NV, US
Las Vegas, NV, US
CEO
A. Stone Douglass
Website
hyphalabs.com
IPO
2012-08-13
CIK 1502966 ISIN US2538252022
Also trades on
Other OTC · DIGP (USD)
Other OTC · FUNI (USD)
Description
Hypha Labs, Inc. focuses on the investigation, development, and market release of bioreactor systems across the United States. Their key offering is the Hypha Micropearl bioreactor, a specialized household device engineered to rapidly cultivate beneficial mushrooms for dietary intake. Founded in 2010, the company is officially based in Las Vegas, Nevada.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.02
+0.00 (+5.68%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
79.4K
Beta
1.45
Float Shares
129.20M
Free Float %
79.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +12.68% | +75.82% | +8.73% | -24.88% | -0.84% | -38.03% | -6.45% | +306.39% | -45.09% | -89.82% | +217.82% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.02
Quality scores
Altman Z-Score
-265.89
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%—
-
EPS growth Medical - Diagnostics & Research: +30.8%-100.0% Q1'26: +67.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%—
-
EBIT margin Medical - Diagnostics & Research: +9.6%—
-
ROIC Medical - Diagnostics & Research: +5.2%— Q1'26: +159.1% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+33.4% Q1'26: +21.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.56× Q1'26: -1.11× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-539.3K
OE per share TTM
0.00
Owner's Yield
-12.08%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
40.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
1.50M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,500,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-29 | DOUGLASS A STONE | Director / Officer | A-Award | A | Common Stock | 4,000,000 | 0.00 | — | 7,500,000 | D | ↗ |
| 2023-01-18 | DOUGLASS A STONE | Director / Officer | A-Award | A | Common Stock | 2,000,000 | 0.00 | — | 3,500,000 | D | ↗ |
| 2021-10-21 | DOUGLASS A STONE | Director / Officer | A-Award | A | Common Stock | 1,500,000 | 0.00 | — | 1,500,000 | — | ↗ |
| 2021-07-01 | Denkin Todd | Officer | A-Award | A | Common Stock | 1,500,000 | 0.00 | — | 2,308,824 | — | ↗ |
| 2021-07-01 | DOUGLASS A STONE | Director | — | D | Stock Option (Right to Buy) | 1,000,000 | 0.06 | 60.0K | 0 | — | ↗ |
| 2021-06-25 | RABEN BRUCE I | Director | A-Award | A | Common Stock | 250,000 | 0.00 | — | 2,390,000 | — | ↗ |
| 2021-06-25 | Hartmann Dennis | Director | A-Award | A | Common Stock | 125,000 | 0.00 | — | 325,000 | — | ↗ |
| 2021-06-02 | RABEN BRUCE I | Director | A-Award | A | Common Stock | 840,000 | 42,000.00 | 35.28B | 2,140,000 | — | ↗ |
| 2021-03-25 | RABEN BRUCE I | Director | A-Award | A | Common Stock | 200,000 | 0.00 | — | 1,300,000 | — | ↗ |
| 2021-03-25 | Peterson Todd A | Officer | A-Award | A | Common Stock | 266,430 | 0.00 | — | 3,828,394 | — | ↗ |
| 2021-03-25 | Hartmann Dennis | Director | A-Award | A | Common Stock | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2021-03-25 | DeFrank Edmond | Director | A-Award | A | Common Stock | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2020-12-30 | RABEN BRUCE I | Director | A-Award | A | Common Stock | 900,000 | 0.02 | 20.3K | 1,100,000 | — | ↗ |
| 2020-12-25 | Peterson Todd A | Officer | A-Award | A | Common Stock | 728,155 | 0.00 | — | 3,561,964 | — | ↗ |
| 2020-09-25 | Peterson Todd A | Officer | A-Award | A | Common Stock | 657,895 | 0.00 | — | 2,833,809 | — | ↗ |
| 2020-06-25 | Peterson Todd A | Officer | A-Award | A | Common Stock | 375,000 | 0.00 | — | 2,175,914 | — | ↗ |
| 2020-03-25 | Peterson Todd A | Officer | A-Award | A | Common Stock | 248,756 | 0.00 | — | 1,800,914 | — | ↗ |
| 2020-03-11 | Remenda Kyle | Officer | A-Award | A | Common Stock | 2,925,000 | 0.06 | 168.2K | 2,925,000 | — | ↗ |
| 2020-03-09 | Remenda Kyle | Officer | A-Award | A | Stock Option (Right to buy) | 750,000 | 0.10 | 75.0K | 750,000 | — | ↗ |
| 2020-03-09 | RABEN BRUCE I | Director | A-Award | A | Stock Option (Right to buy) | 1,000,000 | 0.10 | 100.0K | 1,000,000 | — | ↗ |
| 2020-01-31 | Hartmann Dennis | Director | A-Award | A | Stock Option (Right to buy) | 250,000 | 0.10 | 25.0K | 250,000 | — | ↗ |
| 2020-01-31 | DeFrank Edmond | Director | A-Award | A | Stock Option (Right to buy) | 250,000 | 0.10 | 25.0K | 250,000 | — | ↗ |
| 2020-01-29 | DeFrank Edmond | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-25 | Peterson Todd A | Officer | A-Award | A | Common Stock | 171,233 | 0.00 | — | 1,552,158 | — | ↗ |
| 2019-09-25 | Remenda Kyle | Officer | A-Award | A | Stock Option (Right to buy) | 500,000 | 0.10 | 51.0K | 500,000 | — | ↗ |
| 2019-09-25 | Peterson Todd A | Officer | A-Award | A | Common Stock | 147,059 | 0.00 | — | 1,380,925 | — | ↗ |
| 2019-09-25 | Hartmann Dennis | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-09-25 | Denkin Todd | Director / Officer | A-Award | A | Common Stock | 58,824 | 0.00 | — | 302,370 | — | ↗ |
| 2019-06-25 | Peterson Todd A | Officer | A-Award | A | Common Stock | 104,167 | 0.00 | — | 1,233,866 | — | ↗ |
| 2019-06-25 | Denkin Todd | Director / Officer | A-Award | A | Common Stock | 58,824 | 0.00 | — | 302,370 | — | ↗ |
| 2019-03-25 | Peterson Todd A | Officer | A-Award | A | Common Stock | 73,171 | 0.00 | — | 1,129,699 | — | ↗ |
| 2019-03-25 | Denkin Todd | Director / Officer | A-Award | A | Common Stock | 29,268 | 0.00 | — | 201,879 | — | ↗ |
| 2019-01-07 | RABEN BRUCE I | Director | A-Award | A | Stock Option (Right to buy) | 500,000 | 0.13 | 65.0K | 500,000 | — | ↗ |
| 2019-01-07 | Peterson Todd A | Officer | D-Return | D | Stock Option (Right to buy) | 100,000 | 0.33 | 33.0K | 100,000 | — | ↗ |
| 2019-01-07 | Orser Cindy Sue | Director | A-Award | A | Stock Option (Right to buy) | 500,000 | 0.13 | 65.0K | 500,000 | — | ↗ |
| 2019-01-07 | Denkin Todd | Director / Officer | A-Award | A | Stock Option (Right to buy) | 2,500,000 | 0.13 | 325.0K | 2,500,000 | — | ↗ |
| 2018-12-25 | Peterson Todd A | Officer | A-Award | A | Common Stock | 115,652 | 0.00 | — | 1,056,528 | — | ↗ |
| 2018-12-25 | Denkin Todd | Director / Officer | A-Award | A | Common Stock | 46,261 | 0.00 | — | 172,611 | — | ↗ |
| 2018-09-25 | Peterson Todd A | Officer | A-Award | A | Common Stock | 98,361 | 0.00 | — | 940,876 | — | ↗ |
| 2018-09-25 | Denkin Todd | Director / Officer | A-Award | A | Common Stock | 39,344 | 0.00 | — | 126,350 | — | ↗ |
| 2018-09-12 | RABEN BRUCE I | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-09-12 | Orser Cindy Sue | Director | — | D | Common Stock | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2018-06-25 | Peterson Todd A | Officer | A-Award | A | Common Stock | 78,947 | 0.00 | — | 842,515 | — | ↗ |
| 2018-06-25 | Denkin Todd | Director / Officer | A-Award | A | Common Stock | 31,579 | 0.00 | — | 87,006 | — | ↗ |
| 2018-03-26 | Peterson Todd A | Officer | A-Award | A | Common Stock | 138,568 | 0.00 | — | 763,568 | — | ↗ |
| 2018-03-26 | Denkin Todd | Director / Officer | A-Award | A | Common Stock | 55,427 | 0.00 | — | 55,427 | — | ↗ |
| 2018-03-26 | BIANCO JOSEPH J | Director / Officer | A-Award | A | Common Stock | 207,852 | 0.00 | — | 707,852 | — | ↗ |
| 2017-12-22 | Peterson Todd A | Officer | A-Award | A | Common Stock | 300,000 | 0.00 | — | 625,000 | — | ↗ |
| 2017-12-22 | Denkin Todd | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 0.27 | 135.0K | 500,000 | — | ↗ |
| 2017-12-22 | Axtmayer Alfredo | Director / Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 300,000 | — | ↗ |
| 2017-11-29 | Orser Cindy Sue | Director | — | D | Stock Option (Right to buy) | 100,000 | 0.27 | 27.0K | 0 | — | ↗ |
| 2017-03-01 | Peterson Todd A | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 325,000 | — | ↗ |
| 2017-02-22 | Axtmayer Alfredo | Director | A-Award | A | Common Stock | 100,000 | 0.00 | — | 200,000 | — | ↗ |
| 2017-01-28 | Axtmayer Alfredo | Director | — | D | Common Stock | 0 | 0.00 | — | 100,000 | — | ↗ |
| 2016-09-30 | Peterson Todd A | Officer | A-Award | A | Common Stock | 300,000 | 0.00 | — | 300,000 | — | ↗ |
| 2016-06-21 | Denkin Todd | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 2,500,000 | 0.20 | 500.0K | 2,500,000 | — | ↗ |
| 2016-06-21 | BIANCO JOSEPH J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 4,750,000 | 0.20 | 950.0K | 4,750,000 | — | ↗ |
| 2016-05-09 | BIANCO JOSEPH J | Director | A-Award | A | Common Stock | 500,000 | 0.00 | — | 500,000 | — | ↗ |
| 2015-10-07 | BIANCO JOSEPH J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-06-19 | Peterson Todd A | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-06-01 | Orser Cindy Sue | Director | — | D | Stock Option (Right to buy) | 200,000 | 0.40 | 80.0K | 0 | — | ↗ |
| 2014-12-31 | Denkin Todd | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 5,000,000 | 0.04 | 200.0K | 5,000,000 | — | ↗ |
| 2014-12-31 | Barbee Steven D | Director | A-Award | A | Stock Option (Right to Buy) | 5,000,000 | 0.04 | 200.0K | 5,000,000 | — | ↗ |
| 2014-12-30 | Denkin Todd | Director / Officer | D-Return | D | Common Stock | 4,000,000 | 0.00 | — | 0 | — | ↗ |
| 2014-12-30 | Barbee Steven D | Director | D-Return | D | Common Stock | 5,000,000 | 0.00 | — | 2,500,000 | — | ↗ |
| 2014-06-07 | Raw Alternative, LLC | 10% Owner | — | D | Series A Convertible Preferred Stock, par value $0.001 | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-05-30 | TANNER JOE D | Director | — | D | Common Stock | 0 | 0.00 | — | 500,000 | — | ↗ |
| 2014-05-30 | Barbee Barbee Denny | Director / Officer | A-Award | A | Common Stock | 5,000,000 | 0.00 | — | 7,500,000 | — | ↗ |
| 2014-04-23 | Raw Alternative, LLC | 10% Owner | — | D | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 20,000,000 | — | ↗ |
| 2014-04-09 | Stoppenhagen Eric | Director / Officer / 10% Owner | P-Purchase | A | Series A Convertible Preferred Stock | 27,788 | 0.02 | 555.76 | 99,652 | — | ↗ |
| 2014-04-09 | Denkin Todd | Director / Officer | A-Award | A | Common Stock | 4,000,000 | 0.00 | — | 4,000,000 | — | ↗ |
| 2012-09-30 | Stoppenhagen Eric | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-03-05 | Barbee Barbee Denny | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,500,000 | — | ↗ |
| 2010-10-15 | Stoppenhagen Eric | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 5,000,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
162.52M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| A. Stone Douglass | Chairman, President, Chief Executive Officer, Chief Financial Officer & Secretary | 120.0K | male |
| Craig Ellins | Chief Science Officer | — | male |
| John Frailey | Chief Technical Director | — | male |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FUNI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
